Despite progress in the successful treatment of patients with rheumatoid arthritis (RA) who are using conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), a Greek study has found that a considerable number of patients are still not achieving low disease activity (LDA) despite having been treated following established recommendations for RA therapy.
Despite progress in the successful treatment of patients with rheumatoid arthritis (RA) who are using conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), a Greek study has found that a considerable number (20.9%) of patients are still not achieving low disease activity (LDA) despite having been treated following established recommendations for RA therapy.
The study was published in the June 15, 2018, issue of the Annals of the Rheumatic Diseases.1
The data from the study are based on the experience of 538 patients at a Greek outpatient RA clinic who were followed from January 2006 to December 2017. All patients fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for early RA, had disease duration for less than 1 year, were csDMARD- and bDMARD-naïve, and were treated according to EULAR/ACR recommendations and strategies for RA.
The csDMARDs used to treat patients were:
The following bDMARDs were used:
Small doses of steroids were also administered. During follow up, laboratory findings, treatment decisions and strategies, any drug reactions, and reasons for termination or changes in treatment strategies were recorded. Disease activity was measured with the Disease Activity Score-28 (DAS-28) using the erythrocyte sedimentation rate.
All patients received 1 csDMARD for at least 6 months. The csDMARD of first choice was MTX (58%), followed by LFN (32%), HCQ (8%), and SSZ (2%); the bDMARD of first choice was INF (37%) followed by ETN (32%) and ADA (31%). Seven patients never received bDMARDs because of comorbidities.
The final results were based on data from 517 patients (14 patients were lost; 7 never received bDMARDs). Among the remaining 517 patients, 324 patients (66%) were treated with csDMARDs as monotherapy or in combination, with or without steroids, with significant clinical improvement and sustained low-disease activity (LDA). However, 11 patients (3.2%) from this group neither achieved LDA nor received bDMARDs due to comorbidities. A total of 175 (34%) patients were treated with bDMARDs with or without csDMARDs and/or steroids and the majority demonstrated sustained LDA for a long period of time. Of this group, 31 patients (17.7%) never achieved LDA despite switching and receiving all bDMARDs. Thus, a total of 20.9% of the patients never achieved LDA.
The researchers conclude that their real-life study estimates the significant size of the unmet need among patients with RA despite adherence to established ACR/EULAR—endorsed treatment methods.
Reference
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.